Literature DB >> 18475691

Modulation of macrophage activation by prostaglandins.

L Sautebin1, R Carnuccio, F D'Acquisto, M D Rosa.   

Abstract

The effect of prostaglandtn E(2), iloprost and cAMP on both nitric oxide and tumour necrosis factor-alpha release in J774 macrophages has been studied. Both prostaglandin E(2) and iloprost inhibited, in a concentration-dependent fashion, the lipopolysaccharide-induced generation of nitric oxide and tumour necrosis factor-alpha. The inhibitory effect of these prostanoids seems to be mediated by an increase of the second messenger cAMP since it was mimicked by dibutyryl cAMP and potentiated by the selective type IV phosphodiesterase inhibitor RO-20-1724. Our results suggest that the inhibition of nitric oxide release by prostaglandin E(2) and iloprost in lipopolysaccharide-activated J774 macrophages may be secondary to the inhibition of tumour necrosis factor-alpha generation, which in turn is likely to be mediated by cAMP.

Entities:  

Year:  1996        PMID: 18475691      PMCID: PMC2365772          DOI: 10.1155/S0962935196000026

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  14 in total

1.  Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme.

Authors:  J L Masferrer; K Seibert; B Zweifel; P Needleman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

2.  Nitric oxide: a cytotoxic activated macrophage effector molecule.

Authors:  J B Hibbs; R R Taintor; Z Vavrin; E M Rachlin
Journal:  Biochem Biophys Res Commun       Date:  1988-11-30       Impact factor: 3.575

3.  Interdependence of tumor necrosis factor, prostaglandin E2, and protein synthesis in lipopolysaccharide-exposed rat Kupffer cells.

Authors:  T Peters; U Karck; K Decker
Journal:  Eur J Biochem       Date:  1990-08-17

4.  The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors.

Authors:  M L Reeves; B K Leigh; P J England
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

5.  Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides.

Authors:  H Renz; J H Gong; A Schmidt; M Nain; D Gemsa
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

6.  Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells.

Authors:  S Endres; H J Fülle; B Sinha; D Stoll; C A Dinarello; R Gerzer; P C Weber
Journal:  Immunology       Date:  1991-01       Impact factor: 7.397

7.  Nitric oxide mediates tumor necrosis factor-alpha cytotoxicity in endothelial cells.

Authors:  C Estrada; C Gómez; C Martín; S Moncada; C González
Journal:  Biochem Biophys Res Commun       Date:  1992-07-15       Impact factor: 3.575

8.  Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression.

Authors:  S L Kunkel; M Spengler; M A May; R Spengler; J Larrick; D Remick
Journal:  J Biol Chem       Date:  1988-04-15       Impact factor: 5.157

9.  Interferon-gamma and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages.

Authors:  J C Drapier; J Wietzerbin; J B Hibbs
Journal:  Eur J Immunol       Date:  1988-10       Impact factor: 5.532

10.  Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts.

Authors:  J M Dayer; B Beutler; A Cerami
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

View more
  1 in total

1.  Endogenous PGI2 signaling through IP inhibits neutrophilic lung inflammation in LPS-induced acute lung injury mice model.

Authors:  Shinji Toki; Weisong Zhou; Kasia Goleniewska; Sara Reiss; Daniel E Dulek; Dawn C Newcomb; William E Lawson; R Stokes Peebles
Journal:  Prostaglandins Other Lipid Mediat       Date:  2018-04-13       Impact factor: 3.072

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.